Macimorelin

Overview

Macimorelin is a synthetic peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist at the ghrelin receptor (growth hormone secretagogue receptor type 1a, GHS-R1a). Approved by the FDA in 2017 under the brand name Macrilen, macimorelin is the first and currently only oral agent approved for the diagnosis of adult growth hormone deficiency (AGHD).

The compound was developed by Aeterna Zentaris (initially as AEZS-130) to address a significant clinical gap in endocrine diagnostics. Prior to macimorelin's approval, the diagnosis of AGHD relied on provocative growth hormone stimulation tests using agents such as insulin (insulin tolerance test, ITT), glucagon, arginine, or GHRH-arginine — all requiring injectable administration and, in the case of the ITT, posing non-trivial safety risks including severe hypoglycemia and seizures.

Macimorelin provides a substantially simpler diagnostic protocol: the patient drinks an oral solution, and growth hormone levels are measured via blood draws at specified intervals. This approach has been validated as having diagnostic accuracy comparable to the insulin tolerance test, which is considered the historical gold standard.

Beyond its diagnostic application, macimorelin is pharmacologically related to the broader family of growth hormone secretagogues including GHRP-2, GHRP-6, and ipamorelin, though it is the only member of this class to achieve regulatory approval for any indication.

Structure and Sequence

Macimorelin is not a classical peptide but rather a peptidomimetic — a small molecule designed to mimic the structural features necessary for ghrelin receptor binding:

• Chemical name: 2-methylalanyl-D-tryptophyl-N-[(1S)-1-(formylamino)-5-(4-aminobutyl)pentyl]-alaninamide
• Molecular formula: C26H39N7O4 (free base)
• Molecular weight: approximately 501.6 g/mol (free base); approximately 561.6 g/mol (acetate salt)
• Key structural features: The molecule incorporates a D-tryptophan residue and a formamide-modified lysine analog, mimicking the pharmacophore of ghrelin's N-terminal acylated region. Its small molecular size and peptidomimetic character enable oral absorption, unlike true peptide GH secretagogues.
• Solubility: formulated as granules for reconstitution in water for oral administration

Mechanism of Action

Ghrelin Receptor Agonism

Macimorelin binds to and activates the GHS-R1a (ghrelin receptor), a G-protein coupled receptor expressed in the hypothalamus and anterior pituitary:

Hypothalamic-pituitary pathway:

• GHS-R1a activation on hypothalamic arcuate nucleus neurons stimulates release of growth hormone-releasing hormone (GHRH)
• Simultaneously, GHS-R1a activation suppresses somatostatin release, removing tonic inhibition of GH secretion
• At the pituitary level, GHS-R1a on somatotrope cells directly potentiates GH release in synergy with GHRH signaling
• The net effect is a robust, dose-dependent surge in circulating growth hormone

Diagnostic principle:

• In patients with intact somatotrope function, macimorelin elicits a substantial GH peak (typically above 2.8 ng/mL at the established cutoff)
• In patients with true GH deficiency, somatotrope capacity is insufficient to mount an adequate GH response
• The test discriminates between GH-sufficient and GH-deficient adults with sensitivity and specificity comparable to the insulin tolerance test

Receptor pharmacology:

• Macimorelin is a full agonist at GHS-R1a with nanomolar affinity
• The receptor signals primarily through Gq/11 coupling, activating phospholipase C and increasing intracellular calcium
• Cross-talk with GHRH receptor signaling (Gs-cAMP pathway) on the same somatotrope cell produces synergistic GH release

Research Summary

Pharmacokinetics

• Route: oral (reconstituted granules in water, 0.5 mg/kg body weight)
• Bioavailability: sufficient for diagnostic effect; absolute oral bioavailability not precisely published
• Tmax: approximately 30-90 minutes
• Half-life: approximately 4.1-4.8 hours
• GH response timing: peak GH typically occurs 30-90 minutes post-ingestion; blood samples collected at 30, 45, 60, and 90 minutes
• Metabolism: primarily via CYP3A4 (major) and CYP3A5; potential for drug interactions with strong CYP3A4 inhibitors or inducers
• Food effect: must be administered after an overnight fast (minimum 8 hours); food significantly reduces absorption
• Protein binding: approximately 71% (primarily to albumin and alpha-1 acid glycoprotein)
• Excretion: primarily fecal (approximately 58%); renal (approximately 16%)
• Drug interactions: strong CYP3A4 inhibitors may increase macimorelin exposure and potentially cause false-negative results; CYP3A4 inducers may decrease exposure and cause false-positive results

Common Discussion Topics

Advantages Over the Insulin Tolerance Test

The insulin tolerance test, while considered the gold standard for AGHD diagnosis, carries meaningful risks: severe hypoglycemia, seizures, loss of consciousness, and cardiovascular events in susceptible individuals. It is contraindicated in patients with seizure disorders, cardiovascular disease, and elderly patients. Macimorelin provides comparable diagnostic accuracy with an oral formulation, no hypoglycemia risk, and minimal adverse effects, making it suitable for a much broader patient population.

Drug Interaction Considerations

Macimorelin's dependence on CYP3A4 metabolism introduces clinically relevant drug interaction considerations. Concurrent use of strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin) or inducers (rifampin, phenytoin, carbamazepine) may alter macimorelin exposure and compromise diagnostic accuracy. Clinicians are advised to review concomitant medications before testing and to discontinue interacting agents when feasible.

QTc Prolongation Signal

In clinical development, a mild, transient prolongation of the QTc interval was observed after macimorelin administration (mean increase of approximately 11 ms). While this has not been associated with clinical arrhythmic events, it led to a recommendation to avoid macimorelin in patients with known QT prolongation, uncontrolled heart failure, or concurrent use of QT-prolonging medications. This finding also highlighted the need for baseline ECG assessment in some clinical protocols.

Relationship to Research Peptides

Macimorelin is pharmacologically related to the research peptide secretagogues GHRP-2, GHRP-6, and ipamorelin, all of which stimulate GH release through GHS-R1a agonism. However, macimorelin is uniquely positioned as an FDA-approved diagnostic tool rather than a therapeutic agent. Discussion exists regarding whether the diagnostic validation of macimorelin provides indirect pharmacological validation for the secretagogue mechanism exploited by these research compounds.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Macimorelin (Macrilen) is an FDA-approved diagnostic agent. Always consult a qualified healthcare professional.

Test protocol: Patient must fast overnight (minimum 8 hours). Reconstitute granules in 120 mL water and drink within 30 minutes. Blood samples for GH measurement are collected at 30, 45, 60, and 90 minutes post-ingestion. A peak GH level below 2.8 ng/mL is consistent with adult growth hormone deficiency.

Important considerations: Discontinue strong CYP3A4 inhibitors/inducers before testing when feasible. Avoid in patients with QT prolongation or concurrent QT-prolonging medications. This is a diagnostic agent only, not a therapeutic treatment.

Related Compounds

• GHRP-2 — A hexapeptide growth hormone secretagogue acting on the same ghrelin receptor, used primarily in research settings
• GHRP-6 — Another hexapeptide GHS-R1a agonist with additional appetite-stimulating effects
• Ipamorelin — A selective pentapeptide GH secretagogue with minimal effects on cortisol and prolactin
• Sermorelin — A GHRH analog that stimulates GH release through the complementary GHRH receptor pathway